Screening for prostate cancer.
Prostate cancer is a highly prevalent disease in the Western world. In the United States alone, prostate cancer affects approximately 230,000 men and causes the death of 30,000 American men annually. Several theoretical health care measures may be implemented to decrease the morbidity and mortality of any disease. These measures include prevention, screening, improved curative treatment, and the transformation of an acute lethal disease to a chronic, tolerable one. This summary focuses on the screening aspects of prostate cancer.
Wilson
Shandra S
SS
Department of Urologic Oncology, Anschutz Cancer Center, Denver, CO, USA. shandra.wilson@uchsc.edu
Crawford
E David
ED
D014408:Biomarkers, Tumor / Q000032:analysis; D003362:Cost-Benefit Analysis; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics; D015995:Prevalence; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology; D012680:Sensitivity and Specificity; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen